Search results
Results From The WOW.Com Content Network
Provigil - used to treat excessive sleepiness and narcolepsy Prozac ( fluoxetine ) – an antidepressant of the SSRI class Luminal ( phenobarbital ) – a barbiturate with sedative and hypnotic properties
Modafinil, sold under the brand name Provigil among others, is a central nervous system (CNS) stimulant and eugeroic (wakefulness promoter) medication used primarily to treat narcolepsy, [3] [8] [15] a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. [16]
Chemical structure of modafinil.. This page lists chemical compounds similar to modafinil, known as modafinil analogues and derivatives.These are structural analogues and derivatives of modafinil, a drug that affects dopamine levels in the brain in an unusual way (atypical dopamine reuptake inhibitor or DRI).
The pharmaceutical company Cephalon, the original United States market rights holder of modafinil, has demonstrated initiative in the development of a successor to the prototypical eugeroic. [25]
Modafinil is sold under the brand name Provigil among others. Modafinil is used to treat excessive daytime sleepiness due to narcolepsy , shift work sleep disorder , or obstructive sleep apnea . While it has seen off-label use as a purported cognitive enhancer, the research on its effectiveness for this use is not conclusive. [ 167 ]
At steady state, the systemic exposure for armodafinil is 1.8 times the exposure observed after a single dose. The concentration-time profiles of the (R)-(−)-enantiomer following a single dose of 50 mg Nuvigil or 100 mg Provigil (modafinil being a 1:1 mixture of (R)-(−)- and (S)-(−)- enantiomers
This is the list of Schedule III controlled substances in the United States as defined in section 202 of the Controlled Substances Act (21 U.S.C. § 812) and 21 CFR 1308.13. The following findings are required for substances to be placed in this schedule:
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.